Gina Hong1, Noah Lechtzin2, Denis Hadjiliadis1, Steven M Kawut1,3. 1. Department of Medicine, Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania. 2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 3. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
INTRODUCTION: Prevalence of fungi has been rising in the cystic fibrosis (CF) population. Scedosporium species (spp) is the second most common mold seen in the CF respiratory tract. However, the characteristics associated with Scedosporium isolation and its clinical implications are poorly understood. The goal of this study was to determine clinical factors associated with Scedosporium spp to better understand the mechanisms that may contribute to the emergence of filamentous fungi in CF. METHODS: We conducted a retrospective cohort study of subjects followed in the CF Foundation Patient Registry between January 1, 2010 and December 31, 2012. Patients under 6 years of age, history of solid organ transplantation, and insufficient respiratory culture data were excluded. We used a multivariable logistic regression model to determine demographic data and baseline disease characteristics, medications and co-infections associated with Scedosporium spp recovery in CF sputum. RESULTS: Among 19 023 subjects, prevalence of Scedosporium spp was 615 (3.2%). Older age (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.07, 1.26) and white race (OR 1.69, 95% CI 1.09, 2.63) were the demographic factors associated with Scedosporium spp isolation. Inhaled antibiotic use had a significant association with Scedosporium isolation (OR 2.01, 95% CI 1.61, 2.52). For every additional course of intravenous antibiotics, the odds of Scedosporium isolation increased by 8% (OR 1.08, 95% CI 1.03, 1.14). CONCLUSIONS: The association between inhaled antibiotics and Scedosporium informs us that chronic inhaled antibiotics may be playing a role in Scedosporium isolation. Further investigation to better characterize this relationship is necessary.
INTRODUCTION: Prevalence of fungi has been rising in the cystic fibrosis (CF) population. Scedosporium species (spp) is the second most common mold seen in the CF respiratory tract. However, the characteristics associated with Scedosporium isolation and its clinical implications are poorly understood. The goal of this study was to determine clinical factors associated with Scedosporium spp to better understand the mechanisms that may contribute to the emergence of filamentous fungi in CF. METHODS: We conducted a retrospective cohort study of subjects followed in the CF Foundation Patient Registry between January 1, 2010 and December 31, 2012. Patients under 6 years of age, history of solid organ transplantation, and insufficient respiratory culture data were excluded. We used a multivariable logistic regression model to determine demographic data and baseline disease characteristics, medications and co-infections associated with Scedosporium spp recovery in CF sputum. RESULTS: Among 19 023 subjects, prevalence of Scedosporium spp was 615 (3.2%). Older age (odds ratio [OR] 1.16, 95% confidence interval [CI] 1.07, 1.26) and white race (OR 1.69, 95% CI 1.09, 2.63) were the demographic factors associated with Scedosporium spp isolation. Inhaled antibiotic use had a significant association with Scedosporium isolation (OR 2.01, 95% CI 1.61, 2.52). For every additional course of intravenous antibiotics, the odds of Scedosporium isolation increased by 8% (OR 1.08, 95% CI 1.03, 1.14). CONCLUSIONS: The association between inhaled antibiotics and Scedosporium informs us that chronic inhaled antibiotics may be playing a role in Scedosporium isolation. Further investigation to better characterize this relationship is necessary.
Authors: Lilian Masoud-Landgraf; Alexandra Badura; Ernst Eber; Gebhard Feierl; Egon Marth; Walter Buzina Journal: Med Mycol Date: 2014-02 Impact factor: 4.076
Authors: Min Chen; Nahid Kondori; Shuwen Deng; A H G Gerrits van den Ende; M Lackner; Wanqing Liao; G S de Hoog Journal: Med Mycol Date: 2018-08-01 Impact factor: 4.076
Authors: A Rougeron; S Giraud; A Alastruey-Izquierdo; J Cano-Lira; J Rainer; A Mouhajir; S Le Gal; G Nevez; W Meyer; J P Bouchara Journal: Mycopathologia Date: 2017-09-19 Impact factor: 2.574
Authors: Yuriko Nagano; J Stuart Elborn; B Cherie Millar; James M Walker; Colin E Goldsmith; Jackie Rendall; John E Moore Journal: Med Mycol Date: 2010-02 Impact factor: 4.076
Authors: Christopher R Sudfeld; Elliott C Dasenbrook; William G Merz; Karen C Carroll; Michael P Boyle Journal: J Cyst Fibros Date: 2009-12-31 Impact factor: 5.482
Authors: C C M de Jong; L Slabbers; T G P Engel; J B Yntema; M van Westreenen; P D Croughs; N Roeleveld; R Brimicombe; P E Verweij; J F Meis; P J Merkus Journal: Med Mycol Date: 2020-10-01 Impact factor: 4.076